The Top 5 Biosimilar Articles for the Week of January 10

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of January 10, 2022.

Number 5: A comparative study of PanGen Biotech’s epoetin alfa biosimilar candidate PDA10 and the reference product, Retacrit, demonstrated comparable efficacy and safety.

Number 4: Concerned about patient access to monoclonal antibody medications, including biosimilars, patient advocates in India appealed to the country’s executive administration to spur reforms in biologics regulation.

Number 3: Alvotech became the second biosimilar developer to announce an approval in the Canadian market for a high-concentration, citrate-free adalimumab biosimilar (Simlandi).

Number 2: A strong market and development push for “biobetters” is anticipated by authors of a review of biosimilar and new biologic drug development in ophthalmology.

Number 1: Seeking to position themselves optimally for a share of the adalimumab (Humira) market, Samsung Bioepis and Organon are seeking FDA approval for a biosimilar high-concentration, citrate-free formulation (100 mg/mL) of adalimumab.

To read all of these articles and more, visit centerforbiosimilars.com.